Komori
Business alliance3840VIXTON corporationInformation and Communications, Services and Others

(Progress on Disclosed Matters) Notice Regarding a Business Partnership by a Subsidiary (Execution of a Materials Transfer Agreement)

RMDC has entered into a materials transfer agreement with South Korea's MEDIPOST and begun demonstration testing and joint research on a culture robot using MEDIPOST's cells and novel culture medium. MEDIPOST will pay RMDC approximately ¥1 million in activity costs for Phase 2.

Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
100
¥10,000
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Business alliance
3840VIXTON corporation
Alliance partnerMEDIPOST Co., Ltd.
Details of the alliance
  1. 1

    RMDC will receive cells and novel culture medium held by MEDIPOST and conduct culture compatibility assessments (demonstration testing) using the “culture robot” installed at RMDC's Amagasaki CPF (cell processing facility).

  2. 2

    The parties will progressively optimize cell-seeding timing and conduct preliminary tests on the feasibility of cell culture (Phase 2).

  3. 3

    Research results obtained through the demonstration testing will be used to optimize automated culture robots for promoting the automation of MEDIPOST's cell culture processing facilities.

  4. 4

    Culture data and operation logs accumulated during the demonstration testing will be used by both companies as foundational data for optimizing the next-generation automated culture robot on which they are jointly working, and for developing “Physical AI” algorithms that reproduce the judgment of skilled technicians.

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

About the partner
LocationSouth Korea
Impact on Business Performance

The impact of this matter on the Company's consolidated results for the current fiscal year is expected to be minor.

Alliance start date2 February 2026 (the first day on which discussions began regarding the purpose of the research and the specific initiatives)Contract PeriodResearch period: 2 February 2026 to 30 September 2027
Agreements reached under this partnership
ItemDetails
Name of alliance partnerMEDIPOST Co., Ltd.
Alliance partner's locationSouth Korea
Type of allianceBusiness alliance
Details of the allianceRMDC will receive cells and novel culture medium held by MEDIPOST and conduct culture compatibility assessments (demonstration testing) using the “culture robot” installed at RMDC's Amagasaki CPF (cell processing facility)., The parties will progressively optimize cell-seeding timing and conduct preliminary tests on the feasibility of cell culture (Phase 2)., Research results obtained through the demonstration testing will be used to optimize automated culture robots for promoting the automation of MEDIPOST's cell culture processing facilities., Culture data and operation logs accumulated during the demonstration testing will be used by both companies as foundational data for optimizing the next-generation automated culture robot on which they are jointly working, and for developing “Physical AI” algorithms that reproduce the judgment of skilled technicians.
Contract PeriodResearch period: 2 February 2026 to 30 September 2027
Alliance start date2 February 2026 (the first day on which discussions began regarding the purpose of the research and the specific initiatives)
Impact on Business PerformanceThe impact of this matter on the Company's consolidated results for the current fiscal year is expected to be minor.
Items this document does not state (16)
Alliance partner's business activitiesAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersNumerical targets under the agreementShareholding PolicyDate of board resolutionContract DateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To conduct culture compatibility assessments and joint research as the first concrete step toward implementing factory automation and “Physical AI” using next-generation automated culture robots.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Progress on Disclosed Matters) Notice Regarding a Business Partnership by a Subsidiary (Execution of a Materials Transfer Agreement) | VIXTON corporation (3840) timely disclosure | Komori